Summary

The United States liquid biopsy market is projected to grow at a formidable rate during the forecast period, 2023-2027. The market growth can be attributed to the rising prevalence of cancer and the growing preference for non-invasive treatment procedures. Besides, a rise in tobacco consumption, lifestyle changes, and environmental factor is expected to contribute towards the growth of the United States liquid biopsy market. Additionally, the expansion of infectious diseases such as Hepatitis B and C and increasing health consciousness among the population are anticipated to fuel the market growth.
Cancer is one of the top causes of patient death worldwide, according to the World Health Organization. Due to its superior effectiveness compared to more conventional cancer diagnostic methods, liquid biopsy is in high demand among medical experts to treat cancer. Compared to conventional treatment approaches, liquid biopsy has many benefits, including improved patient comfort, acquired drug resistance, cheaper cost, therapy monitoring, early prognosis, and tumor heterogeneity identification.
Since liquid biopsy is a quick, painless procedure that offers a superior alternative to invasive surgical biopsies, it has completely changed the way cancer is treated. Through a small sample, it assists the medical specialists in learning a wealth of information about the tumor. The process is short and gives accurate information on the situation right now. Currently, liquid biopsy therapy involves the use of patient blood, saliva, and urine samples to collect circulating tumor DNA (ctDNA), circulating tumor cells (CTC), and exosomes. The primary factor driving liquid biopsy's high demand among medical experts is its non-invasiveness. Since only 5 milliliters of blood are needed, it is less intrusive, more convenient, and quicker for patients than other procedures.
Companion diagnostics are tests or assays essential in supplying cancer patients with knowledge about the efficiency and safety of using the related biological product or treatment. The drug development process can be optimized and improved with companion diagnostics, which aid in discovering safer medications with greater therapeutic efficacy. They reduce the possibility of error, lower the cost of the pharmaceuticals, and increase the efficiency of the drug production process. Drug manufacturering companies, research, and diagnostic facilities are more likely to use companion diagnostics due to the increased demand for effective treatments and medications. Moreover, the high penetration of companion diagnostics, owing to increased awareness of the techniques' benefits, is expected to boost the growth of the liquid biopsy market in the United States.
The United States liquid biopsy market is divided into product & services, circulating biomarker, technology, application, end user, regional distribution, and company. Based on the product & services, the market is divided into assay kits, instruments, services. The assay kits are expected to register the highest growth in the United States liquid biopsy market, owing to their ease of handling and affordability.
Market players operating in the United liquid biopsy market are Thermo Fischer Scientific, Inc., Guardant Health, Inc., Biocept, Inc., Roche Diagnostics Corporation, Myriad Genetics, Inc., Exact Sciences Corporation, Illumina, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., NeoGenomics, Inc., Vortex Biosciences, Inc., Exosome Diagnostics, Inc., Agena Bioscience, Inc., MedGenome Inc., Personal Genome Diagnostics, Inc., among others.
Years considered for this report:
Historical Years: 2017-2020
Base Year: 2021
Estimated Year: 2022
Forecast Period: 2023–2027
Objective of the Study:
• To analyze the historical growth in the market size of the United States liquid biopsy from 2017 to 2021.
• To estimate and forecast the market size of United States liquid biopsy market from 2023 to 2027 and growth rate until 2027.
• To classify and forecast the United States liquid biopsy market based on product & service, circulating biomarker, technology, application, end user, region, and company.
• To identify the dominant region or segment in the United States liquid biopsy market.
• To identify drivers and challenges for the United States liquid biopsy market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the United States liquid biopsy market.
• To identify and analyze the profiles of leading players operating in the United States liquid biopsy market.
• To identify key sustainable strategies adopted by market players in United States liquid biopsy market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers and service providers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, service providers, distribution channels and presence of all major players across the country.
TechSci Research calculated the market size of the United States liquid biopsy market using a top-down approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience:
• Market research and consulting firms
• Government bodies such as regulating authorities and policy makers
• Organizations, forums, and alliances
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as product manufacturers, service providers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, United States liquid biopsy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• United States Liquid Biopsy Market, By Product & Services:
o Assay Kits
o Instruments
o Services
• United States Liquid Biopsy Market, By Circulating Biomarker:
o Circulating Tumor Cells
o Circulating Tumor DNA (ctDNA)
o Cell-free DNA (cfDNA)
o Others
• United States Liquid Biopsy Market, By Technology:
o Multi-gene Parallel Analysis using NGS
o Single-gene Analysis using PCR Microarrays
• United States Liquid Biopsy Market, By Application:
o Cancer
o Non-Cancer
• United States Liquid Biopsy Market, By End User:
o Hospitals & Clinics
o Reference Laboratories
o Others
• United States Liquid Biopsy Market, By Region:
o South
o West
o Mid-West
o North-East
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in United States liquid biopsy market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on United States Liquid Biopsy Market
4. Voice of Customer
5. Executive Summary
6. United States Liquid Biopsy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product & Services (Assay Kits, Instruments, Services)
6.2.2. By Circulating Biomarker (Circulating Tumor Cells, Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Others)
6.2.3. By Technology (Multi-gene Parallel Analysis using NGS v/s Single-gene Analysis using PCR Microarrays)
6.2.4. By Application (Cancer v/s Non-Cancer)
6.2.5. By End User (Hospitals & Clinics, Reference Laboratories, Others)
6.2.6. By Company (2021)
6.2.7. By Region
6.3. Product Market Map
7. North-East Liquid Biopsy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product & Services
7.2.2. By Circulating Biomarker
7.2.3. By Technology
7.2.4. By Application
7.2.5. By End User
8. North-East Liquid Biopsy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product & Services
8.2.2. By Circulating Biomarker
8.2.3. By Technology
8.2.4. By Application
8.2.5. By End User
9. Mid-West Liquid Biopsy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product & Services
9.2.2. By Circulating Biomarker
9.2.3. By Technology
9.2.4. By Application
9.2.5. By End User
10. West Liquid Biopsy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product & Services
10.2.2. By Circulating Biomarker
10.2.3. By Technology
10.2.4. By Application
10.2.5. By End User
11. South Liquid Biopsy Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Product & Services
11.2.2. By Circulating Biomarker
11.2.3. By Technology
11.2.4. By Application
11.2.5. By End User
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Policy & Regulatory Landscape
15. United States Economic Profile
16. Competitive Landscape
16.1. Thermo Fischer Scientific, Inc.
16.2. Guardant Health, Inc.
16.3. Biocept, Inc.
16.4. Roche Diagnostics Corporation
16.5. Myriad Genetics, Inc.
16.6. Exact Sciences Corporation
16.7. Illumina, Inc.
16.8. Bio-Rad Laboratories, Inc.
16.9. Biocept, Inc.
16.10. NeoGenomics, Inc.
16.11. Vortex Biosciences, Inc.
16.12. Exosome Diagnostics, Inc.
16.13. Agena Bioscience, Inc.
16.14. MedGenome Inc.
16.15. Personal Genome Diagnostics, Inc.
17. Strategic Recommendations
18. About Us & Disclaimer